The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Electronic patient-reported outcomes with vital sign monitoring versus usual care during trastuzumab deruxtecan treatment for metastatic breast cancer: Updated results from the PRO-DUCE study.
 
Yuichiro Kikawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
 
Yukari Uemura
Honoraria - Chugai Pharma
Speakers' Bureau - Lilly; Pfizer
 
Tetsuhiko Taira
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa-Kirin,; Lilly; MSD; Pfizer; Taiho Pharmaceutical
 
Chiyoe Kitagawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; MSD; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Abbvie; ALX Oncology; Daiichi Sankyo/Astra Zeneca; MSD; Ono Yakuhin; Sanofi
 
Hideki Maeda
Honoraria - AstraZeneca; Lilly Japan; PDRadiopharma; Pfizer
 
Hiroaki Kato
No Relationships to Disclose
 
Naoki Hashimoto
No Relationships to Disclose
 
Mitsuchika Hosoda
No Relationships to Disclose
 
Yohei Hamanaka
No Relationships to Disclose
 
Yuko Tanabe
Research Funding - Lilly (Inst); MSD (Inst)
 
Tatsuya Yoshida
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Pfizer; Taiho Pharmaceutical
 
Kaori Tane
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Pfizer
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo
 
Daisuke Takabatake
No Relationships to Disclose
 
Takashi Ishikawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; MSD; Pfizer
Research Funding - Chugai Pharma; Lilly; Nihonkayaku
 
Takayuki Iwamoto
Research Funding - Pfizer (Inst)
 
Takeshi Yamaguchi
No Relationships to Disclose
 
Daisuke Takiguchi
Employment - Daiichi Sankyo Co, Ltd
 
Hirofumi Mukai
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Takeda
 
Naruto Taira
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kirin Pharmaceuticals; Lilly; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Kirin Pharmaceuticals (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
 
Takafumi Sangai
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Kaken Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; Maruho; Miyarisan pharmaceutical; MSD; Nihonkayaku; Novartis; PDRadiopharma; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Kyowa Kirin International